Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jun 18;9(6):1909.
doi: 10.3390/jcm9061909.

Cholesterol in Relation to COVID-19: Should We Care about It?

Affiliations
Editorial

Cholesterol in Relation to COVID-19: Should We Care about It?

Dina Radenkovic et al. J Clin Med. .

Abstract

Current data suggest that infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing corona virus disease-19 (COVID-19) seems to follow a more severe clinical course in patients with cardiovascular disease (CVD), hypertension, and overweight/obesity. It appears that lipid-lowering pharmacological interventions, in particular statins, might reduce the risk of cardiovascular complications caused by COVID-19 and might potentially have an additional antiviral activity. It has been shown that high cholesterol levels are associated with more lipid rafts, subdomains of the plasma membrane that can harbour angiotensin-converting enzyme 2 (ACE2) receptors for the S-protein of SARS-CoV-2. Evidence of the importance of cholesterol for viral entry into host cells could suggest a role for cholesterol-lowering therapies in reducing viral infectivity. In addition to their lipid-lowering and plaque-stabilisation effects, statins possess pleiotropic effects including anti-inflammatory, immunomodulatory, and antithrombotic activities. Lower rates of mortality and intubation have been reported in studies investigating statin therapy in influenza infection, and statin therapy was shown to increase viral clearance from the blood during chronic hepatitis C infection. Statins may also serve as potential SARS-CoV-2 main protease inhibitors, thereby contributing to the control of viral infection. In this review, we elaborate on the role of cholesterol level in the process of the coronavirus infection and provide a critical appraisal on the potential of statins in reducing the severity, duration, and complications of COVID-19.

Keywords: COVID-19; SARS-CoV-2; atherosclerosis; cholesterol; coronavirus; lipid-lowering therapy; statins.

PubMed Disclaimer

Conflict of interest statement

M.P. has received honoraria and/or travel reimbursement for events sponsored by Amgen, Alfasigma, Mylan, Neopharmed Gentili, Sanofi; M.B.—speakers bureau: Abbott/Mylan, Abbott Vascular, Actavis, Akcea, Amgen, Biofarm, KRKA, MSD, Polpharma, Sanofi-Aventis, Servier and Valeant; consultant to Abbott Vascular, Akcea, Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, Lilly, MSD, Polfarmex, Resverlogix, Sanofi-Aventis; Grants from Sanofi and Valeant. All other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Proposed mechanism of the role of cholesterol and statins in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. (A) Lipid rafts rich in cholesterol serve as docking sites for angiotensin-converting enzyme 2 (ACE2) receptors and viral attachment via the S protein of SARS-CoV-2, which is then taken into the cells by clathrin. In addition, acute infection with SARS-COV-2 and macrophages via paracrine factors can lead to plaque instability and embolization causing occlusion of distal microvasculature. (B) Statins disrupt lipid rafts and viral binding; reduce cholesterol; and have plaque stabilising, antithrombotic, and anti-inflammatory properties.

References

    1. Nabavi S., Habtemariam S., Clementi E., Berindan-Neagoe I., Cismaru C., Rasekhian M., Banach M., Izadi M., Bagheri M., Bagheri M., et al. Lessons learned from SARS-CoV and MERS-CoV: FDA-approved abelson tyrosine-protein kinase 2 inhibitors may help us combat SARS-CoV-2. Arch. Med. Sci. 2020;16:519–521. doi: 10.5114/aoms.2020.94504. - DOI - PMC - PubMed
    1. Dolinski D., Dolinska B., Zmaczynska-Witek B., Banach M., Kulesza W. Unrealistic optimism in the time of coronavirus pandemic: May it help to kill, if so-whom: Disease or the person? J. Clin. Med. 2020;9:1464. doi: 10.3390/jcm9051464. - DOI - PMC - PubMed
    1. Katsiki N., Banach M., Mikhailidis D. Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic. Arch. Med. Sci. 2020;16:485–489. doi: 10.5114/aoms.2020.94503. - DOI - PMC - PubMed
    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-Infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585. - DOI - PMC - PubMed
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648. - DOI - PubMed

Publication types

LinkOut - more resources